Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANKL) in heterotopic vascular ossification

Thrombosis and Haemostasis

Volumn 94, Issue 6, 2005, Pages 1335-1337

  Al Fakhri, Nadia ^a   Hofbauer, Lorenz C ^a   Preissner, Klaus T ^b   Franke, Folker E ^b   Schoppet, Michael ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AMPUTATION; ARTERY DISEASE; ARTICLE; BLOOD VESSEL CALCIFICATION; CASE REPORT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GANGRENE; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERLIPOPROTEINEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; OBESITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECONDARY HYPERPARATHYROIDISM; X RAY;

EID: 29244483904     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-06-1335     Document Type: Article

References (14)

1. Doherty TM, Asotra K, Fitzpatrick LA et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci (USA) 2003; 100: 11201-6.
2. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-5.
3. Collin-Osdoby P. Regulation of vascular calcification by osteoclastregulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-57.
4. Emery JG, McDonnell P, Burke MB et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-7.
5. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-8.
6. Schoppet M, Al-Fakhri N, Franke FE et al. Localization of osteoprotegerin (OPG), TNF-related apoptosis-inducing ligand (TRAIL), and receptor activator of NF-κB ligand (RANKL) in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104-12.
7. Colucci S, Brunetti G, Rizzi R et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004; 104: 3722-30.
8. Doherty TM, Uzui H, Fitzpatrick LA et al. Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J 2002; 16: 577-82.
9. Min H, Morony S, Sarosi I et al. Osteoprotegenn reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-74.
10. Iribarren C, Sidney S, Sternfeld B et al. Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA 2000; 283: 2810-5.
11. Zhang J, Fu M, Myles D et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002; 521: 180-4.
12. Proudfoot D, Skepper JN, Hegyi L et al. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87: 1055-62.
13. Gochuico BR, Zhang J, Ma BY et al. TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol 2000; 278: L1045-50.
14. Price PA, June HH, Buckley JR et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-6.